Tissue factor pathway inhibitor (TFPI) improved CXCL12-mediated migration of chronic lymphocytic leukemia (CLL) cells by increasing CXCR7 expression, suggesting that CXCL12-CXCR7 was involved in organ infiltration in CLL patients 95. Here, CXCL12 is linked to B-cell chronic lymphocytic leukemia.